E-TRANS fentanyl ALZA

Current Opinion in Investigational Drugs

Volumn 3, Issue 3, 2002, Pages 463-469

  Mystakidou, Kyriaki ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; BUPRENORPHINE; CORTICOSTEROID; FENTANYL; LIDOCAINE; METHADONE; MORPHINE; MU OPIATE RECEPTOR; OHM 3507; OHM 3568; OPIATE AGONIST; REMIFENTANIL; SUFENTANIL; UNCLASSIFIED DRUG;

ACUTE DISEASE; BIOTECHNOLOGY; BOLUS INJECTION; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ELECTRIC CURRENT; ELECTRODE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOXEMIA; MOLECULE; NEUROLOGIC DISEASE; PAIN; PAIN ASSESSMENT; PASSIVE MOVEMENT; PATIENT CONTROLLED ANALGESIA; PHASE 3 CLINICAL TRIAL; RESPIRATION DEPRESSION; REVIEW; SKIN MANIFESTATION; SKIN PENETRATION; STRUCTURE ACTIVITY RELATION; TRANSDERMAL PATCH;

ANALGESICS, OPIOID; ANIMALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DRUG DELIVERY SYSTEMS; FENTANYL; HUMANS; PAIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036228915     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Structure-transport relationships in transdermal iontophoresis
2. Annual Report 1994 - ALZA Corp
3. Annual Report 1995 - ALZA Corp
4. Pharmacological profile of a potent, efficacious fentanyl derivative in rhesus monkeys
5. Fentanyl remaining in a transdermal system following three days of continuous use
6. Transdermally administered fentanyl for pain management
7. Absorption characteristics of transdermally administered fentanyl
8. The transdermal administration of fentanyl in the treatment of postoperative pain: Pharmacokinetics and pharmacodynamic effects
9. Transdermal fentanyl for pain control in patients with cancer
10. Iontophoresis of dexamethasone: Laboratory studies
11. The iontophoresis of fentanyl citrate in humans
12. Fentanyl blood concentration-analgesic response relationship in the treatment of postoperative pain
13. ALZA and Janssen to collaborate on E-TRANS pain products/New generation of products to address chronic and acute pain markets
14. Crescendo Pharmaceuticals Corp to fund development of E-TRANS fentanyl product for chronic pain
15. Behavioral effects and binding affinities of the fentanyl derivative OHM3507
16. Allergan
17. ALZA Corp outlines strategy for growth in 2000
18. Transdermal fentanyl compared with parenteral buprenorphine in post-surgical pain in swine: A case study
19. Effect of current density on pharmacokinetics following continuous or intermittent input from a fentanyl electrotransport system
20. Global Healthcare Bulletin
21. Transdermal fentanyl: New preparation. An alternative to morphine
22. Clinical pharmacokinetics of transdermal opioids: Focus on transdermal fentanyl
23. Transdermal fentanyl: Clinical pharmacology
24. Duragesic transdermal patch: Post-mortem tissue distribution of fentanyl in 25 cases
25. Continuous administration of fentanyl for postoperative pain: A comparison of the epidural, intravenous, and transdermal routes
26. Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update
27. Clinical uses of fentanyl, sufentanil, and alfentanil
28. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain
29. Oral transmucosal fentanyl citrate: Randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients
30. A comparison of transdermal fentanyl versus epidural morphine for analgesia in dogs undergoing major orthopedic surgery
31. Evaluation of transdermal fentanyl patches for analgesia in cats undergoing onychectomy
32. Comparison of transdermal fentanyl and intramuscular oxymorphone on post-operative behaviour after ovariohysterectomy in dogs
33. Transdermal fentanyl disposition in elderly subjects
34. Fatal fentanyl intoxication following excessive transdermal application
35. Opioid intoxication. Inappropriate administration of transdermal fentanyl
36. Long-term treatment of cancer pain with transdermal fentanyl
37. Fentanyl transdermal system. Pain management at home
38. Transdermal fentanyl in uncontrolled cancer pain: Titration on a day-to-day basis as a procedure for safe and effective dose finding - A pilot study in 20 patients
39. Transdermal fentanyl use in hospice home-care patients with chronic cancer pain
40. Direct conversion from oral morphine to transdermal fentanyl: A multicenter study in patients with cancer pain
41. Respiratory changes during treatment of postoperative pain with high dose transdermal fentanyl
42. Quality of life and cancer pain: Satisfaction and side effects with transdermal fentanyl versus oral morphine
43. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life. The TTS-fentanyl comparative trial group
44. Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain
45. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control
46. New strategies in opioid therapy for cancer pain
47. Reproducible fentanyl doses delivered intermittently at different time intervals from an electrotransport system
48. Fentanyl delivery from an electrotransport system: Delivery is a function of total current, not duration of current
49. In vivo iontophoresis of fentanyl and sufentanil in rats: Pharmacokinetics and acute antinociceptive effects
50. Analgesic effect of the transdermal fentanyl patch during and after feline ovariohysterectomy
51. Transdermal delivery of drugs by iontophoresis: A review
52. Direct imaging of molecular transport through skin
53. What are the pathways of ionotrophoretic current flow through mammalian skin?
54. EMLA cream: An improved local anesthetic-review of current literature
55. Double-blind evaluation of a lignocaine-prilocaine cream (EMLA) in children: Effect on the pain associated with venous cannulation
56. Alternatives to oral opioids for cancer pain
57. Package inserts and other dosage guidelines are especially useful with new analgesics and new analgesic delivery systems
58. New developments in patient-controlled postoperative analgesia
59. Patient controlled analgesia: Drug options, infusion schedules, and other considerations
60. Iontophoretic delivery of model inorganic and drug ions
61. Iontophoresis of a model peptide across human skin in vitro: Effects of iontophoresis protocol, pH, and ionic strength on peptide flux and skin impedance
62. Transdermal ion migration
63. Painless cauterization of spider veins with the use of iontophoretic local anesthesia
64. Iontophoretic administration of lidocaine anesthesia in office practice
65. A prospective, nonrandomized study of iontophoresis, wrist splinting, and anti-inflammatory medication in treatment of early-mid carpal tunnel syndrome
66. Iontophoretic delivery of morphine for postoperative analgesia
67. The quantity and distribution of radiolabeled dexamethasone delivered to tissue by iontophoresis
68. In vitro study of low-frequency ultrasound-enhanced transdermal transport of fentanyl and caffeine across human and hairless rat skin
69. In vivo efficacy and safety of skin electroporation
70. Transdermal delivery of fentanyl: Rapid onset of analgesia using skin electroporation
71. Transdermal delivery of fentanyl by electroporation. II. Mechanisms involved in drug transport
72. Clinical pharmacokinetics of fentanyl and its newer derivatives
73. Plasma protein binding and distribution of fentanyl, sufentanil, afentanil and lofentanil in blood
74. Postoperative demand for analgesics in relation to individual levels of endorphins and substance P in cerebrospinal fluid
75. Stress-induced plasma beta-endorphin immunoreactivity may predict postoperative morphine usage
76. Ventilatory depression related to plasma fentanyl concentrations during and after anesthesia in humans
77. Absorption and bioavailability of oral transmucosal fentanyl citrate
78. Introduction of anti-inflammatory drugs by iontophoresis: Double blind study
79. Iontophoresis
80. Transdermal iontophoretic delivery of therapeutic peptides/proteins (I) insulin